Related Experiment Video
Updated: Oct 13, 2025
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma
Valentin-Florian Rauca1,2, Laura Patras1, Lavinia Luput1
1Department of Molecular Biology and Biotechnology, and Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, Babes-Bolyai University, 5-7 Clinicilor Street, 400006, Cluj-Napoca, Romania.
Abstract:
Anti-angiogenic therapies for melanoma have not yet been translated into meaningful clinical benefit for patients, due to the development of drug-induced resistance in cancer cells, mainly caused by hypoxia-inducible factor 1α (HIF-1α) overexpression and enhanced oxidative stress mediated by tumor-associated macrophages (TAMs). Our previous study demonstrated synergistic antitumor actions of simvastatin (SIM) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on an in vitro melanoma model via suppression of the aggressive phenotype of melanoma cells and inhibition of TAMs-mediated angiogenesis. Therefore, we took the advantage of long circulating liposomes (LCL) superior tumor targeting capacity to efficiently deliver SIM and DMXAA to B16.F10 melanoma in vivo, with the final aim of improving the outcome of the anti-angiogenic therapy. Thus, we assessed the effects of this novel combined tumor-targeted treatment on s.c. B16.F10 murine melanoma growth and on the production of critical markers involved in tumor development and progression. Our results showed that the combined liposomal therapy almost totally inhibited (> 90%) the growth of melanoma tumors, due to the enhancement of anti-angiogenic effects of LCL-DMXAA by LCL-SIM and simultaneous induction of a pro-apoptotic state of tumor cells in the tumor microenvironment (TME). These effects were accompanied by the partial re-education of TAMs towards an M1 phenotype and augmented by combined therapy-induced suppression of major invasion and metastasis promoters (HIF-1α, pAP-1 c-Jun, and MMPs). Thus, this novel therapy holds the potential to remodel the TME, by suppressing its most important malignant biological capabilities.
Insights
This study developed a novel liposomal therapy combining simvastatin and DMXAA to overcome melanoma resistance to anti-angiogenic treatments. The combined therapy significantly inhibited tumor growth by targeting tumor cells and associated macrophages.
Area of Science:
- Oncology
- Nanomedicine
- Cancer Biology
Background:
- Anti-angiogenic therapies for melanoma show limited clinical success due to drug resistance, often driven by hypoxia-inducible factor 1α (HIF-1α) and tumor-associated macrophages (TAMs).
- Previous research indicated synergistic antitumor effects of simvastatin (SIM) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in vitro by suppressing melanoma aggressiveness and TAM-mediated angiogenesis.
Purpose of the Study:
- To evaluate the efficacy of long-circulating liposomes (LCL) delivering SIM and DMXAA for targeted therapy against B16.F10 melanoma in vivo.
- To assess the impact of this combined liposomal therapy on melanoma growth and key markers of tumor progression.
Main Methods:
- Utilized long-circulating liposomes (LCL) for co-delivery of simvastatin (SIM) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to subcutaneous B16.F10 murine melanoma models.
- Assessed tumor growth inhibition, anti-angiogenic effects, apoptosis induction, TAM phenotype modulation, and suppression of invasion/metastasis markers (HIF-1α, c-Jun, MMPs).
Main Results:
- The combined liposomal therapy achieved over 90% inhibition of melanoma tumor growth.
- Therapy enhanced anti-angiogenic effects, induced tumor cell apoptosis, partially shifted TAMs towards an M1 phenotype, and suppressed HIF-1α, c-Jun, and MMPs.
Conclusions:
- This novel co-delivery liposomal therapy demonstrates significant potential to overcome melanoma resistance and improve anti-angiogenic therapy outcomes.
- The treatment effectively remodels the tumor microenvironment by inhibiting critical malignant capabilities, offering a promising strategy for melanoma treatment.
